Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309750819> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4309750819 abstract "Abstract Background The maintenance treatment of metastatic colorectal cancer (mCRC) after first-line treatment is still controversial. Meta analysis was used to analyze whether there was survival benefit after first-line treatment of mCRC from the effectiveness and safety of capecitabine maintenance treatment. Methods In April, 2022, the following biomedical electronic databases were searched: PubMed, EMBASE, Google Scholar and Cochrane Library, including capecitabine maintenance therapy versus active monitoring randomized controlled trials (RCTs) and clinical trials (CT) of mCRC patients after first-line treatment. The primary outcome was progression free survival (PFS) of capecitabine maintenance therapy, and secondary outcomes included overall survival (OS), toxicity, and BRAF and RAS gene mutation status. Extract the hazard ratio (HR) of 95% confidence interval (CI) or HR data that can calculate 95% confidence interval (CI). All data were analyzed by Revman5.4 software. Results Five eligible studies included 1672 patients. Meta analysis showed that capecitabine maintenance therapy had more significant benefits for PFS than active monitoring PFS (HR 0.59; 95%CI: 0.52–0.66; P < 0.00001); In addition, capecitabine maintenance therapy was also beneficial to OS (HR 0.85; 95% CI: 0.76–0.95; p = 0.003). Subgroup analysis showed that BRAF/RAS wild-type patients were more likely to benefit from capecitabine maintenance, based on the significant interaction between BRAF/RAS status (P = 0.002). The most common adverse reaction was hand-foot skin reaction to capecitabine maintenance therapy compared with active monitoring (2.3% vs 0.4%; OR 5.53, 95%CI: 1.42–21.58, I 2 = 0%, P = 0.01) was slightly increased. Conclusion This meta-analysis suggests that capecitabine was beneficial in PFS and OS compared with active monitoring. Adverse reactions are common but acceptable. Subgroup analysis showed that the differential effect of capecitabine maintenance treatment was beneficial to BARF/RAS wild-type patients. In specific cases, capecitabine monotherapy maintenance therapy can be considered, such as cumulative toxicity to fluoropyrimidine or patient rejection, especially for BRAF/RAS wild-type patients." @default.
- W4309750819 created "2022-11-29" @default.
- W4309750819 creator A5005627824 @default.
- W4309750819 creator A5034579880 @default.
- W4309750819 creator A5052529616 @default.
- W4309750819 creator A5073978256 @default.
- W4309750819 creator A5077672672 @default.
- W4309750819 creator A5079524559 @default.
- W4309750819 creator A5087128953 @default.
- W4309750819 date "2022-11-21" @default.
- W4309750819 modified "2023-09-24" @default.
- W4309750819 title "Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trials" @default.
- W4309750819 cites W1985213644 @default.
- W4309750819 cites W2005023050 @default.
- W4309750819 cites W2103502575 @default.
- W4309750819 cites W2137417501 @default.
- W4309750819 cites W2142263087 @default.
- W4309750819 cites W2288210984 @default.
- W4309750819 cites W2330350802 @default.
- W4309750819 cites W2671324896 @default.
- W4309750819 cites W2901082418 @default.
- W4309750819 cites W2902220632 @default.
- W4309750819 cites W2965454487 @default.
- W4309750819 cites W3024882806 @default.
- W4309750819 cites W3113077386 @default.
- W4309750819 cites W3118615836 @default.
- W4309750819 cites W3150599205 @default.
- W4309750819 cites W3185426497 @default.
- W4309750819 cites W4200293254 @default.
- W4309750819 cites W4225773257 @default.
- W4309750819 doi "https://doi.org/10.21203/rs.3.rs-2054864/v1" @default.
- W4309750819 hasPublicationYear "2022" @default.
- W4309750819 type Work @default.
- W4309750819 citedByCount "0" @default.
- W4309750819 crossrefType "posted-content" @default.
- W4309750819 hasAuthorship W4309750819A5005627824 @default.
- W4309750819 hasAuthorship W4309750819A5034579880 @default.
- W4309750819 hasAuthorship W4309750819A5052529616 @default.
- W4309750819 hasAuthorship W4309750819A5073978256 @default.
- W4309750819 hasAuthorship W4309750819A5077672672 @default.
- W4309750819 hasAuthorship W4309750819A5079524559 @default.
- W4309750819 hasAuthorship W4309750819A5087128953 @default.
- W4309750819 hasBestOaLocation W43097508191 @default.
- W4309750819 hasConcept C121608353 @default.
- W4309750819 hasConcept C126322002 @default.
- W4309750819 hasConcept C143998085 @default.
- W4309750819 hasConcept C168563851 @default.
- W4309750819 hasConcept C197934379 @default.
- W4309750819 hasConcept C207103383 @default.
- W4309750819 hasConcept C2776694085 @default.
- W4309750819 hasConcept C2777909004 @default.
- W4309750819 hasConcept C2778283404 @default.
- W4309750819 hasConcept C2780739268 @default.
- W4309750819 hasConcept C44249647 @default.
- W4309750819 hasConcept C526805850 @default.
- W4309750819 hasConcept C71924100 @default.
- W4309750819 hasConcept C95190672 @default.
- W4309750819 hasConceptScore W4309750819C121608353 @default.
- W4309750819 hasConceptScore W4309750819C126322002 @default.
- W4309750819 hasConceptScore W4309750819C143998085 @default.
- W4309750819 hasConceptScore W4309750819C168563851 @default.
- W4309750819 hasConceptScore W4309750819C197934379 @default.
- W4309750819 hasConceptScore W4309750819C207103383 @default.
- W4309750819 hasConceptScore W4309750819C2776694085 @default.
- W4309750819 hasConceptScore W4309750819C2777909004 @default.
- W4309750819 hasConceptScore W4309750819C2778283404 @default.
- W4309750819 hasConceptScore W4309750819C2780739268 @default.
- W4309750819 hasConceptScore W4309750819C44249647 @default.
- W4309750819 hasConceptScore W4309750819C526805850 @default.
- W4309750819 hasConceptScore W4309750819C71924100 @default.
- W4309750819 hasConceptScore W4309750819C95190672 @default.
- W4309750819 hasLocation W43097508191 @default.
- W4309750819 hasOpenAccess W4309750819 @default.
- W4309750819 hasPrimaryLocation W43097508191 @default.
- W4309750819 hasRelatedWork W1900595920 @default.
- W4309750819 hasRelatedWork W2056185445 @default.
- W4309750819 hasRelatedWork W2599763536 @default.
- W4309750819 hasRelatedWork W2748373020 @default.
- W4309750819 hasRelatedWork W2889691785 @default.
- W4309750819 hasRelatedWork W2969350423 @default.
- W4309750819 hasRelatedWork W3185003217 @default.
- W4309750819 hasRelatedWork W4206071870 @default.
- W4309750819 hasRelatedWork W4237493426 @default.
- W4309750819 hasRelatedWork W4309750819 @default.
- W4309750819 isParatext "false" @default.
- W4309750819 isRetracted "false" @default.
- W4309750819 workType "article" @default.